Literature DB >> 22820970

Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.

R Ordemann, J Stöhlmacher, B Beuthien-Baumann, I Platzek, J van den Hoff, F Kroschinsky, J M Middeke, U Platzbecker, C Zietz, M Bornhäuser, G Ehninger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22820970     DOI： 10.1007/s00277-012-1524-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  4 in total

Review 1.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

2.  Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report.

Authors:  Shalin Kothari; Najam Ud-Din; Michele Lisi; Thomas Coyle
Journal:  J Med Case Rep       Date:  2016-06-14

3.  Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib.

Authors:  Carolina Valeria Mahuad; María de Los Ángeles Vicente Repáraz; Marta E Zerga; María Florencia Aizpurua; Claudia Casali; Gonzalo Garate
Journal:  Rare Tumors       Date:  2016-06-28

Review 4.  Non-Coding RNA Networks in ALK-Positive Anaplastic-Large Cell Lymphoma.

Authors:  Steffen Fuchs; Julian Naderi; Fabienne Meggetto
Journal:  Int J Mol Sci       Date:  2019-04-30       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.